EX-99.1 2 ea029296201ex99-1.htm PRESS RELEASE ISSUED BY SPECTRAL AI, INC. ON JUNE 1, 2026 Exhibit 99.1 Spectral AI Announces Voting Results of Annual Meeting of Stockholders Provides Update and Outlook Following Receipt of FDA De Novo Clearance for DeepView® System for Burn Indication DALLAS, TX - June 1, 2026 - Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced results from its 2026 Annual Meeting of Stockholders, held on May 29, 2026. The Company also provided an overview of its accomplishments to date and targeted milestones for 2026 following the receipt of De Novo Classification for its DeepView® System from the U.S. Food and Drug Administration (“FDA”). 2026 Annual Meeting of Stockholders A total of 17,267,570 shares representing 54.3% of the Company’s total shares outstanding were represented at the meeting, either in person or by proxy. All three of the proposals set forth by the Company were approved by its stockholders. The voting results are detailed below. Five directors were elected to serve o…
Open exhibit ↗Current Report · Items 5.07, 7.01, 9.01 · 8-K
Spectral AI, Inc.
MDAINASDAQEQUITYCurrent
Submission of Matters to a Vote of Security Holders · Regulation FD Disclosure
Item 5.07 Submission of Matters to a Vote of Security Holders The 2026 Annual Meeting (the “Annual Meeting”) of Stockholders of the Company was held on May 29, 2026. A total of 31,823,985 shares of the Company’s Common Stock, par value $0.0001 per share (“Common Stock”), were eligible and entitled to vote at the Annual Meeting and a total of 17,267,570 shares of the Company’s Common Stock were rep…
Company context
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView System. The DeepView System is a predictive diagnostic device that offers physicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal to exceed the current standard of care, the DeepView System provides fast and accurate treatment insights to improve patient outcomes and reduce healthcare costs. Spectral AI has been named to TIME’s list of World’s Top HealthTech companies 2025. For more information about the DeepView System, visit www.spectral-ai.com.
Current securities
Recent company filings
- Regulation FD DisclosureSep 15, 2026
- Results of Operations and Financial Condition · Regulation FD DisclosureAug 12, 2026
- 10-Q filingAug 11, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureJul 8, 2026
- 4 filingJun 1, 2026